Full Title
A Phase II Study of Induction PD-1 Blockade in Subjects with Locally Advanced Mismatch Repair Deficient Solid TumorsPurpose
Deficient mismatch repair (dMMR) happens when a cell becomes unable to repair mistakes that happen during the normal process of cell division. Standard treatments for early-stage rectal cancer and solid tumors including endometrial cancer include chemotherapy, radiation therapy, and surgery. In this study, researchers are assessing the safety and effectiveness of giving the investigational immunotherapy dostarlimab first in people with locally advanced MMR solid tumors or in people with early stage dMMR endometrial cancer and a strong desire for fertility preservation. Doctors will then evaluate patients’ response to treatment before considering standard chemoradiation and/or surgery. Patients whose tumors respond completely to dostarlimab alone can be followed with close surveillance and no surgery.
Dostarlimab is a type of medication called an antibody. It blocks another protein (PD-1) that usually acts as a “brake” on the immune system, thereby enabling the immune system to detect and destroy cancer cells.
Contact
If you have a diagnosis of an MMRd solid tumor, please contact Dr. Andrea Cercek at 646-888-4189 for more information and to inquire about eligibility for this study.
If you have a diagnosis of endometrial cancer, please contact Dr. Paul Johannet at 646-888-5327 for more information and to inquire about eligibility for the study.